Skip Navigation
Skip to contents
Filter

ARTICLE TYPE

PUBLICATION DATE

6 results
Display

Evaluation of pharmacokinetic interactions between amoxicillin, clarithromycin, and the potassium-competitive acid blocker YH4808 in healthy subjects

Lee WY, Oh E, Cui M, Kim CO, Lim Y, Kim H, Park H, Yoon S, Park MS, Hong T

YH4808 is a novel potassium-competitive acid blocker that was developed as a therapeutic agent for gastric acid-related diseases; it may replace proton pump inhibitors, which are widely used in combination...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pharmacokinetics and pharmacodynamics of a fixed-dose combination of gemigliptin/metformin sustained release 25/500 mg compared to the loose combination in healthy male subjects

Jin X, Kim E, Huh KY, Hwang I, Cho JY, Yu KS, Lee S

A fixed-dose combination (FDC) of gemigliptin/metformin can improve the medication adherence in patients with type 2 diabetes mellitus (T2DM). In this study, the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Survey of physicians' views on the clinical implementation of pharmacogenomics-based personalized therapy

Kim WY, Kim HS, Oh M, Shin JG

Despite quantitative increases and qualitative advances in pharmacogenomics (PGx) research, the clinical implementation of PGx-based personalized therapy has still been limited. The objective of this study was to assess physicians'...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor

Gu N, Park SI, Chung H, Jin X, Lee S, Kim TE

Type 2 diabetes mellitus is a multifactorial condition characterized by high level of sugar in the blood. To control hyperglycemia, combination therapy is recommended if monotherapy fails to achieve glycemic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Complex influences of gut microbiome metabolism on various drug responses

Chae S, Kim DJ, Cho JY

The gut microbiome closely interacts with the host, and it has a major influence on drug response. Many studies have reported the possible microbial influences on drugs and the possible...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
What is the optimal fit-for-purpose design in an oncology first-in-human trial?: 3+3 vs. Bayesian Logistic Regression Model

Yum SY

CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr